Genetix Biotherapeutics

Genetix Biotherapeutics is dedicated to transforming lives through curative therapies. 
 
Formerly bluebird bio, Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company delivering genetic therapies for severe rare diseases. The company has three FDA-approved therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time treatments address the underlying cause of disease and can offer lasting benefits to patients and families. With decades of scientific innovation & clinical data from hundreds of treated patients, Genetix is positioned to more effectively deliver life-changing genetic therapies. Entering this new era, we are building an ecosystem to expand awareness and access for thousands of untreated patients—sharpening our focus on commercial execution, scaling access, and improving the treatment experience for patients, families, and providers. 

Community guidelines: bit.ly/4nAuCWY